Purpose

To find predictive factors of neovascular glaucoma (NVG) development in eyes with anterior segment neovascularization without glaucoma (ASNVWG), and poor visual outcomes in eyes that have already developed NVG.

Design

Retrospective, clinical cohort studies.

Methods

A retrospective chart review was performed on 106 eyes of 94 patients with ASNVWG and 245 eyes of 225 patients with NVG. Measured outcomes included the development of NVG at any time point of the disease for the ASNVWG arm, and a visual acuity of ≤20/200 at 6 months after initial presentation for the NVG arm.

Results

Overall, 25% of ASNVWG eyes progressed to NVG. Progression was associated with retinal vein occlusion (RVO) (P < .01), lower median presenting BCVA (P < .01), and concurrent traction retinal detachments (TRDs) (P = .025). Sixty-eight percent of NVG eyes had a BCVA of ≤20/200 by 6-month follow-up, which was associated with RVO (P = .005), vitreous hemorrhage on presentation (P = .001), and no panretinal photocoagulation (PRP) treatments (P < .001). BCVA >20/200 at 6 months was associated with ≥1 PRP or intravitreal bevacizumab (IVB) treatment within 1 week of presentation or ≥3 PRP or IVB treatments overall (P < .001).

Conclusion

RVO, presenting visual acuity, and concurrent TRD are risk factors for NVG in eyes with ASNVWG. In eyes with NVG, RVO and concurrent vitreous hemorrhage are risk factors for ≤20/200 vision at 6 months, whereas treatment with ≥1 PRP or IVB within 1 week of presentation, or ≥3 treatments of PRP or IVB within 6 months are protective.

中文翻译：

---

新生血管性青光眼和无青光眼的眼前节新生血管的视觉结果

目的

寻找无青光眼的眼前节新生血管形成 (ASNVWG) 的眼睛中新生血管性青光眼 (NVG) 发展的预测因素，以及已经发展成 NVG 的眼睛的不良视觉结果。

设计

回顾性临床队列研究。

方法

对 94 名 ASNVWG 患者的 106 只眼和 225 名 NVG 患者的 245 只眼进行了回顾性图表审查。测量的结果包括 ASNVWG 臂在疾病的任何时间点的 NVG 发展，以及 NVG 臂在初次就诊后 6 个月时的视力≤20/200。

结果

总体而言，25% 的 ASNVWG 眼睛进展为 NVG。进展与视网膜静脉阻塞 (RVO) ( P < .01)、呈现 BCVA 的中位数较低 ( P < .01) 和并发牵引性视网膜脱离 (TRD) ( P  = .025) 相关。在 6 个月的随访中，68% 的 NVG 眼的 BCVA ≤20/200，这与 RVO ( P  = .005)、就诊时玻璃体出血 ( P  = .001) 和无全视网膜光凝相关(PRP) 治疗 ( P < .001)。6 个月时 BCVA >20/200 与 1 周内≥1 个 PRP 或玻璃体内贝伐单抗 (IVB) 治疗或≥3 个 PRP 或 IVB 治疗相关（P < .001）。

结论

RVO、呈现视力和并发 TRD 是 ASNVWG 眼中 NVG 的危险因素。在患有 NVG 的眼睛中，RVO 和并发玻璃体出血是 6 个月时视力≤20/200 的危险因素，而在发病 1 周内接受 ≥1 次 PRP 或 IVB 治疗，或在 6 个月内接受 ≥3 次 PRP 或 IVB 治疗具有保护作用.